JOT + rolapitant

**JOT + rolapitant** is a combination regimen used for the prevention of chemotherapy-induced nausea and vomiting (CINV), particularly the delayed phase. Rolapitant is a selective, long-acting **neurokinin-1 (NK1) receptor antagonist** that blocks substance P signaling in the gut and central nervous system to inhibit emetic signals triggered by emetogenic chemotherapy. **JOT** likely refers to a **5-HT3 receptor antagonist** (e.g., josamfetamine, JOT201, or similar), which targets serotonin receptors in the gut and brain to prevent acute nausea and vomiting; this combination is administered alongside dexamethasone, a corticosteroid that reduces inflammation and emetic response, forming a standard triplet antiemetic therapy for highly or moderately emetogenic chemotherapy such as cisplatin-based regimens. Developed for adult cancer patients, it addresses unmet needs in delayed CINV (>24 hours post-chemotherapy) with a single oral dose of rolapitant (180 mg) on day 1, minimizing drug interactions compared to alternatives like aprepitant.